Study Finds Genetic Clues to Development of Head and Neck Cancer

Mar 12, 2020

Daniel Schramek Daniel Schramek

 

A study involving a U of T researcher has identified a common molecular mechanism that fuels cancer growth in up to 70 per cent of head and neck cancer patients, shedding light on possible new therapeutic strategies.

The study was led by Daniel Schramek, a Canada Research Chair in functional cancer genomics at the University of Toronto and Kierans/Janigan Cancer Research Scientist at Sinai Health’s Lunenfeld-Tanenbaum Research Institute.

It looked at about 500 rare mutations in genes associated with head and neck cancer. The findings will appear Friday in the journal Science.

“A clear pattern emerged when we tested these 500 genes,” says Schramek, an assistant professor in the faculty of medicine in the department of molecular genetics.

“Almost all the genes we identified as promoting the cancer were not independent from each other, but influenced the same growth regulatory pathway,” says Schramek.

Head and neck cancer is the sixth most common and one of the deadliest cancers in the world. More than 4,300 Canadians will develop cancer of the head and neck this year and nearly 1,600 will die from it.

Sampath Loganathan, a postdoctoral fellow who led the project in the Schramek lab, said the results point to new possible treatments that target the NOTCH pathway, potentially opening up new therapeutic strategies for many patients.

“We are optimistic that this type of approach will reduce the immense complexity of cancer,” Loganathan said. “While there are many different gene mutations found in head and neck cancer, most are pulling on the same rope. We are now focused on how best to cut it.”

Scientists have long focused their research efforts on frequently mutated genes in cancers, despite knowing that tumours contain many more rare changes.

To determine the linkage between the rare mutations, Schramek’s team used a novel CRISPR gene editing approach in mice, allowing them to test 500 mutations at once. Their method significantly reduced the amount of time needed to perform the study.

Schramek’s team is now applying the same approach to other cancers, such as breast, brain and pancreas, looking for other rare mutations that affect the same pathway.

The research was done in collaboration with the Ontario Institute of Cancer Research and supported by Canadian Institute of Health Research, the Terry Fox Research Institute and the Human Frontier of Science Program.

Tweets

UofT Medicine
@uoftmedicine
“It’s really important to me that we are able to change non-inclusive narratives that are so prevalent in not only… https://t.co/mS0r1YVEBl
UofT Medicine
@uoftmedicine
RT : Meet Dr. Arnav Agarwal, an internal medicine resident physician and today’s Front-line Hero. Colleague Sameer Kushw… https://t.co/jLoDzjlhCA
UofT Medicine
@uoftmedicine
RT : Canadians are accustomed to seeing on the daily news, advising us to “just stay home” during the… https://t.co/zhOhwhHxSO

Researchers are mobilizing against the novel SARS-CoV-2 coronavirus and COVID-19.

Make a gift and support their important work.
Apr
20 – 24
Clinical & Experimental Radiobiology Course 2020
Course | 9:00am–5:00pm
Apr 22 Translational Research Program: On-Campus Info Session Spring 2020
Other | 5:00pm–6:00pm
May 1 Refugee Health Primer: Optimizing Primary Care for Refugee Newcomers 2020
Conference | 8:00am–5:00pm
May 6 WebPac Training
Workshop/Seminar | 3:00pm–5:00pm
May 9 Science Rendezvous U of T St. George
Other | 11:00am–4:00pm
May 14 Department of Psychiatry Continuing Professional & Practice Development Day
Symposium | 8:15am–3:45pm
May
20 – 21
Conference on Cancer Stem Cells and Oncology Research
Conference | 9:00am–5:30pm